Merchants Bancorp
For the period ended Dec 31, 2023. Filed Mar 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 12, 2024
MBIN$53.57+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2023 and 2022
December 31, 2023 and 2022
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · 2023 · 2022 | ||||||
| Assets · · | ||||||
| Cash and due from banks | | $15,592 | | $22,170 | ||
| Interest-earning demand accounts | | 568,830 | | 203,994 | ||
| Cash and cash equivalents | | 584,422 | | 226,164 | ||
| Securities purchased under agreements to resell | | 3,349 | | 3,464 | ||
| Mortgage loans in process of securitization | | 110,599 | | 154,194 | ||
| Securities available for sale ($722,497 and $0 utilizing fair value option, respectively) | | 1,113,687 | | 323,337 | ||
| Securities held to maturity ($1,203,535 and $1,118,966 at fair value, respectively) | | | 1,204,217 | | | 1,119,078 |
| Federal Home Loan Bank (FHLB) stock | | 48,578 | | 39,130 | ||
| Loans held for sale (includes $86,663 and $82,192 at fair value, respectively) | | 3,144,756 | | 2,910,576 | ||
| Loans receivable, net of allowance for credit losses on loans of $71,752 and $44,014, respectively | | 10,127,801 | | 7,426,858 | ||
| Premises and equipment, net | | 42,342 | | 35,438 | ||
| Servicing rights | | 158,457 | | 146,248 | ||
| Interest receivable | | 91,346 | | 56,262 | ||
| Goodwill | | 15,845 | | 15,845 | ||
| Intangible assets, net | | 742 | | 1,186 | ||
| Other assets and receivables | | 306,375 | | 157,447 | ||
| Total assets | | $16,952,516 | | $12,615,227 | ||
| Liabilities and Shareholders' Equity | | | | | ||
| Liabilities | | | ||||
| Deposits | | | ||||
| Noninterest-bearing | | $520,070 | | $326,875 | ||
| Interest-bearing | | 13,541,390 | | 9,744,470 | ||
| Total deposits | | 14,061,460 | | 10,071,345 | ||
| Borrowings | | 964,127 | | 930,392 | ||
| Deferred tax liabilities | | 19,923 | | 19,613 | ||
| Other liabilities | | 205,922 | | 134,138 | ||
| Total liabilities | | 15,251,432 | | 11,155,488 | ||
| Commitments and Contingencies | | | ||||
| Shareholders' Equity | | | ||||
| Common stock, without par value | | | ||||
| Authorized - 75,000,000 shares | | | | | ||
| Issued and outstanding - 43,242,928 shares at December 31, 2023 and 43,113,127 shares at December 31, 2022 | | 140,365 | | 137,781 | ||
| Preferred stock, without par value - 5,000,000 total shares authorized | | | | | | |
| 7% Series A Preferred stock - $25 per share liquidation preference | | | | | ||
| Authorized - 3,500,000 shares | | | | | ||
| Issued and outstanding - 2,081,800 shares | | 50,221 | | 50,221 | ||
| 6% Series B Preferred stock - $1,000 per share liquidation preference | | | | | ||
| Authorized - 125,000 shares | | | | | ||
| Issued and outstanding - 125,000 shares (equivalent to 5,000,000 depositary shares) | | 120,844 | | 120,844 | ||
| 6% Series C Preferred stock - $1,000 per share liquidation preference | | | | | | |
| Authorized - 200,000 shares | | | | | | |
| Issued and outstanding - 196,181 shares (equivalent to 7,847,233 depositary shares) | | | 191,084 | | | 191,084 |
| 8.25% Series D Preferred stock - $1,000 per share liquidation preference | | | | | | |
| Authorized - 300,000 shares | | | | | | |
| Issued and outstanding - 142,500 shares (equivalent to 5,700,000 depositary shares) | | | 137,459 | | | 137,459 |
| Retained earnings | | 1,063,599 | | 832,871 | ||
| Accumulated other comprehensive loss | | (2,488) | | (10,521) | ||
| Total shareholders' equity | | 1,701,084 | | 1,459,739 | ||
| Total liabilities and shareholders' equity | | $16,952,516 | | $12,615,227 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.